Qihan Biotech Unveils its Program to Develop Immunologically Privileged Human Stem Cells for Allogeneic Cell Therapies

Post Reply
curncman
Posts: 617
Joined: Fri Jun 26, 2020 8:27 am

Qihan Biotech Unveils its Program to Develop Immunologically Privileged Human Stem Cells for Allogeneic Cell Therapies

Post by curncman »

Qihan Biotech Unveils its Program to Develop Immunologically Privileged Human Stem Cells for Allogeneic Cell Therapies

HANGZHOU, China--(BUSINESS WIRE)-- Qihan Biotech, a leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today disclosed the initiation of a program to create immunologically privileged human stem cells to enable the development of improved allogeneic cell therapies.

In collaboration with an undisclosed leader in the production and differentiation of clinical, GMP grade human stem cells, Qihan will leverage its proprietary genome editing technology to reduce the immunogenicity of human stem cells, thus limiting their ability to provoke an immune response. Once differentiated into different cell types, the cells have the potential to be used as universal, allogeneic therapies while reducing or eliminating the need for the patient to receive immunosuppressive drugs.

“Cell therapy is quickly becoming an indispensable weapon against cancer and other serious diseases, yet the technology behind cell therapy leaves much room for improvement. Autologous, or personalized, cell therapies can be prohibitively expensive, while allogeneic approaches to cell therapy still require the patient to be administered immunosuppressive drugs and have been prone to rejection by the immune system,” said Luhan Yang, Ph.D., CEO of Qihan Biotech. “To address these obstacles and realize the full potential of allogeneic cell therapies, the Qihan team is using our proprietary multiplexable gene editing technology, in combination with our extensive expertise in transplantation immunology, to create immunologically privileged human stem cells. Based on our progress to date, we are excited to announce that we have begun to employ this approach in clinical grade, GMP stem cells to enable the advancement of our first cell therapy products for human clinical trials.”
curncman
Posts: 617
Joined: Fri Jun 26, 2020 8:27 am

Personalized Stem Cells Announces Licensing Agreement for its Allogeneic Stem Cell Program Including COVID-19 Therapy Pe

Post by curncman »

Personalized Stem Cells Announces Licensing Agreement for its Allogeneic Stem Cell Program Including COVID-19 Therapy
Personalized Stem Cells enters exclusive licensing agreement with Sorrento Therapeutics for allogeneic stem cell platform including COVID-19 therapy candidate.

https://www.wfmj.com/story/42765253/per ... 19-therapy

Personalized Stem Cells enters exclusive licensing agreement with Sorrento Therapeutics for allogeneic stem cell platform including COVID-19 therapy candidate.

By partnering with Sorrento Therapeutics, we expect to see an acceleration in the COVID-19 development program with potential global reach.”— Dr. Bob Harman, PSC CEO
POWAY, CALIFORNIA, US, October 14, 2020 /EINPresswire.com/ -- Personalized Stem Cells, Inc. (PSC) announced today that it has entered into an exclusive license agreement with Sorrento Therapeutics (Nasdaq: SRNE, "Sorrento") to grant global rights to its adipose-derived allogeneic mesenchymal stem cell (MSC) program. This program already has an FDA-approved IND and initial phase 1 clinical trial for patients suffering from acute respiratory distress associated with COVID-19.

PSC applied for this IND with the FDA in April 2020 at the request of the White House Coronavirus Task Force. PSC received approval from the FDA in July of 2020 and immediately began the process of hospital site selection. This Phase 1 study is designed to explore safety and preliminary efficacy of an adipose-derived allogeneic MSC product candidate.

Earlier this year, PSC published a peer-reviewed scientific article on the rationale behind using stem cells to treat COVID-19. With the rapid upswing in positive cases, it is more important than ever to get new therapeutics into testing and approved. Sorrento Therapeutics has a platform of other non-cellular therapies and diagnostics in development and this license provides it's development team with a stem cell product to round out their offerings. Stem cells represent a treatment modality with high potential to help in the fight against COVID-19 as a stand-alone therapy or in synergy with other product candidates in Sorrento’s pipeline.

PSC CEO, Dr. Bob Harman, stated, “Stem cell doses are already produced, quality checked, and ready for clinical trial use in hospitalized patients. By partnering with Sorrento Therapeutics, we expect to see an acceleration in the COVID-19 development program with potential global reach.”

Dr. Henry Ji, Chairman and CEO of Sorrento stated, “Completing this licensing agreement with PSC allows Sorrento to enrich an already comprehensive pipeline of potential therapeutic solutions against COVID-19.”

This licensing deal provides an upfront payment of $3.5 million and future milestone and royalty payments. This capital will be used to support PSC's active and ongoing autologous stem cell program in the areas of orthopedics, pain, and traumatic brain injury.

PSC wants to acknowledge Allan Camaisa (CEO) and the team at Calidi Biotherapeutics (calidibio.com) for our long-term collaboration and for providing the stem cell lines used to manufacture the cells for this initial COVID-19 IND program. PSC also thanks the staff at sister company and CMO, VetStem Biopharma, for the manufacturing and regulatory support that made this FDA Phase 1 clearance and licensing deal a reality.

For those interested in more information about becoming involved with PSC, please click here.
Post Reply